1832 Asset Management
MRTX

1832 Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

1832 Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-22,500
Closed -$2.36M – 771
2019
Q2 		$2.36M Buy
+22,500
New +$1.75M 0.01% 402

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

1832 Asset Management's MRTX Position: Q3 2019 in Review

1832 Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2019, closing a stake of 22,500 shares — an estimated $2.36M sold.

1832 Asset Management first reported a position in MRTX in Q2 2019 and held it in 1 quarter. The position peaked at $2.36M in Q2 2019. 177 funds tracked by Wall St. Rank hold MRTX as of Q3 2019.

  • 1832 Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • 1832 Asset Management sold 22,500 Mirati Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $2.36M.
  • 1832 Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • 1832 Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $2.36M in Q2 2019.
  • 177 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2019.

Based on 1832 Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.